BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, Tanida S, Mizoshita T, Kasugai K, Joh T. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J Clin Biochem Nutr. 2010;47:53-58. [PMID: 20664731 DOI: 10.3164/jcbn.10-10] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Fujioka T, Aoyama N, Sakai K, Miwa Y, Kudo M, Kawashima J, Matsubara Y, Miwa J, Yakabi K. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J Gastroenterol 2012;47:276-83. [DOI: 10.1007/s00535-011-0487-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
2 Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ, Kang BK, Oak JH, Jung SH. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011;26:785-90. [PMID: 21655065 DOI: 10.3346/jkms.2011.26.6.785] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
3 Huang X, Sun X, Yu X, Qian H. WITHDRAWN: Efficacy and safety of Sijunzi decoction for peptic ulcers: a systematic review and meta-analysis. Journal of Traditional Chinese Medical Sciences 2018. [DOI: 10.1016/j.jtcms.2018.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Horie R, Handa O, Ando T, Ose T, Murakami T, Suzuki N, Sendo R, Imamoto E, Itoh Y. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan. Helicobacter 2020;25. [DOI: 10.1111/hel.12698] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Nishizawa T, Suzuki H, Suzuki M, Takahashi M, Hibi T. Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy. J Clin Biochem Nutr. 2012;51:114-116. [PMID: 22962528 DOI: 10.3164/jcbn.d-11-00029r1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
6 Asaoka D, Nagahara A, Matsuhisa T, Takahashi S, Tokunaga K, Kawai T, Kawakami K, Suzuki H, Suzuki M, Nishizawa T. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area. Helicobacter. 2013;18:468-472. [PMID: 23773231 DOI: 10.1111/hel.12063] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
7 Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34. [PMID: 22457599 DOI: 10.2147/ceg.s25419] [Cited by in Crossref: 90] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
8 Santos RS, Dakwar GR, Xiong R, Forier K, Remaut K, Stremersch S, Guimarães N, Fontenete S, Wengel J, Leite M, Figueiredo C, De Smedt SC, Braeckmans K, Azevedo NF. Effect of Native Gastric Mucus on in vivo Hybridization Therapies Directed at Helicobacter pylori. Mol Ther Nucleic Acids 2015;4:e269. [PMID: 26645765 DOI: 10.1038/mtna.2015.46] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sapmaz F, Kalkan IH, Güliter S, Atasoy P. Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments. Eur J Intern Med. 2014;25:224-229. [PMID: 24268371 DOI: 10.1016/j.ejim.2013.11.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
10 Satoh K, Yoshino J, Akamatsu T, Itoh T, Kato M, Kamada T, Takagi A, Chiba T, Nomura S, Mizokami Y. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol. 2016;51:177-194. [PMID: 26879862 DOI: 10.1007/s00535-016-1166-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 53] [Article Influence: 12.3] [Reference Citation Analysis]
11 Saracino IM, Zaccaro C, Re GL, Vaira D, Holton J. The Effects of Two Novel Copper-Based Formulations on Helicobacter pylori. Antibiotics (Basel) 2013;2:265-73. [PMID: 27029303 DOI: 10.3390/antibiotics2020265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Handa O, Naito Y, Osawa M, Murao T, Matsumoto H, Umegaki E, Shiotani A. Nutrients and probiotics: current trends in their use to eradicate Helicobacter pylori. J Clin Biochem Nutr 2020;67:26-8. [PMID: 32801465 DOI: 10.3164/jcbn.20-51] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Kim SY, Lee SW, Hyun JJ, Jung SW, Koo JS, Yim HJ, Park JJ, Chun HJ, Choi JH. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple “concomitant” therapy and 7-day standard triple therapy. J Clin Gastroenterol. 2013;47:21-24. [PMID: 22647826 DOI: 10.1097/mcg.0b013e3182548ad4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
14 Nishizawa T, Suzuki H, Maekawa T, Harada N, Toyokawa T, Kuwai T, Ohara M, Suzuki T, Kawanishi M, Noguchi K, Yoshio T, Katsushima S, Tsuruta H, Masuda E, Tanaka M, Katayama S, Kawamura N, Nishizawa Y, Hibi T, Takahashi M. Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction. World J Gastroenterol 2012; 18(21): 2735-2738 [PMID: 22690086 DOI: 10.3748/wjg.v18.i21.2735] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
15 Eed EM, Hawash YA, Khalifa AS, Alsharif KF, Alghamdi SA, Saber T, Ismail KA, Shehab-Eldeen SA. Molecular diagnosis of Helicobacter pylori antibiotic resistance in the Taif region, Saudi Arabia. Microbiol Immunol 2019;63:199-205. [PMID: 31045263 DOI: 10.1111/1348-0421.12686] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
16 Huang X, Liu Y, Lin Z, Wu B, Nong G, Chen Y, Lu Y, Ji X, Zhou X, Suo B, Chen Q, Wei J. Minimum inhibitory concentrations of commonly used antibiotics against Helicobacter Pylori: A multicenter study in South China. PLoS One 2021;16:e0256225. [PMID: 34473713 DOI: 10.1371/journal.pone.0256225] [Reference Citation Analysis]
17 Jheng GH, Wu IC, Shih HY, Wu MC, Kuo FC, Hu HM, Liu CJ, Hsu WH, Hu CT, Bair MJ, Kuo CH, Wu DC, Hsu PI. Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection. Biomed Res Int 2015;2015:163960. [PMID: 26090383 DOI: 10.1155/2015/163960] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
18 Mansour NM, Hashash JG, El-Halabi M, Ghaith O, Maasri K, Sukkarieh I, Malli A, Sharara AI. A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2011;23:865-870. [PMID: 21811161 DOI: 10.1097/meg.0b013e3283496502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
19 Ozeki K, Furuta T, Ojima T. Association Between Patients' Immunoglobulin E Levels and Difficulty Eradicating Helicobacter pylori. Clin Exp Gastroenterol 2021;14:311-6. [PMID: 34345177 DOI: 10.2147/CEG.S322512] [Reference Citation Analysis]
20 Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama Y, Tanaka E. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19:214-220. [PMID: 24758533 DOI: 10.1111/hel.12124] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
21 Akpinar Z, Akay S, Unsal B. Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth. Arab Journal of Gastroenterology 2017;18:58-61. [DOI: 10.1016/j.ajg.2017.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Alkim H, Iscan M, Oz F. Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey. Libyan J Med. 2011;6. [PMID: 21912572 DOI: 10.3402/ljm.v6i0.8412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
23 Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter. 2013;18:129-134. [PMID: 23121338 DOI: 10.1111/hel.12017] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
24 Ma J, Hiratsuka T, Etoh T, Akada J, Fujishima H, Shiraishi N, Yamaoka Y, Inomata M. Anti-proliferation effect of blue light-emitting diodes against antibiotic-resistant Helicobacter pylori: Blue LED against H. pylori. Journal of Gastroenterology and Hepatology 2018;33:1492-9. [DOI: 10.1111/jgh.14066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Okimoto T, Mizukami K, Ogawa R, Okamoto K, Shuto M, Fukuda K, Kodama M, Murakami K. Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes. J Clin Biochem Nutr 2016;59:149-53. [PMID: 27698544 DOI: 10.3164/jcbn.16-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Nishizawa T, Masaoka T, Kanai T. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European Gastroenterol J 2016;4:380-7. [PMID: 27403304 DOI: 10.1177/2050640615618043] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
27 Lim HC, Lee YJ, An B, Lee SW, Lee YC, Moon BS. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19:455-461. [PMID: 25231089 DOI: 10.1111/hel.12147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
28 Wu TS, Hu HM, Kuo FC, Kuo CH. Eradication of Helicobacter pylori infection. Kaohsiung J Med Sci. 2014;30:167-172. [PMID: 24656156 DOI: 10.1016/j.kjms.2013.11.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
29 Mayderry DW. Letter in response to Relationship between primary eradication of Helicobacter pylori and drinking habits in women: collaborative research between a pharmacy and a clinic. Epidemiol Infect 2020;148:e2. [PMID: 31918787 DOI: 10.1017/S095026881900219X] [Reference Citation Analysis]
30 Okimoto K, Arai M, Saito K, Minemura S, Maruoka D, Matsumura T, Nakagawa T, Katsuno T, Ishii C, Murata S, Watanabe M, Nomura F, Yokosuka O. Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies. Int Sch Res Notices 2014;2014:631501. [PMID: 27379339 DOI: 10.1155/2014/631501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
31 Sharara AI, Sarkis FS, El-Halabi MM, Malli A, Mansour NM, Azar C, Eloubeidi MA, Mourad FH, Barada K, Sukkarieh I. Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection. United European Gastroenterol J 2014;2:179-88. [PMID: 25360301 DOI: 10.1177/2050640614530919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
32 Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A prospective randomized study. Eur J Clin Pharmacol. 2013;69:1709-1715. [PMID: 23695545 DOI: 10.1007/s00228-013-1524-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
33 Ye H, Liu Y, Li N, Yu J, Cheng H, Li J, Zhang XZ. Anti-Helicobacter pylori activities of Chenopodium ambrosioides L. in vitro and in vivoWorld J Gastroenterol 2015; 21(14): 4178-4183 [PMID: 25892867 DOI: 10.3748/wjg.v21.i14.4178] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
34 Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 2014; 20(43): 16029-16036 [PMID: 25473155 DOI: 10.3748/wjg.v20.i43.16029] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
35 Anthony O'connor JP, O'morain CA. Letter: the ethics of using inferior regimens in H. pylori randomised trials - invited comment. Aliment Pharmacol Ther 2012;35:854-6. [DOI: 10.1111/j.1365-2036.2011.04951.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Choi HS, Chun HJ, Park SH, Keum B, Seo YS, Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, Ryu HS. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012; 18(19): 2377-2382 [PMID: 22654429 DOI: 10.3748/wjg.v18.i19.2377] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
37 Hori K, Miwa H, Matsumoto T. Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter. 2011;16:234-240. [PMID: 21585610 DOI: 10.1111/j.1523-5378.2011.00842.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
38 Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34:1255-1268. [PMID: 22017749 DOI: 10.1111/j.1365-2036.2011.04887.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
39 Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Uygun A. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. Eur J Intern Med. 2012;23:165-168. [PMID: 22284248 DOI: 10.1016/j.ejim.2011.02.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
40 Nishizawa T, Maekawa T, Watanabe N, Harada N, Hosoda Y, Yoshinaga M, Yoshio T, Ohta H, Inoue S, Toyokawa T, Yamashita H, Saito H, Kuwai T, Katayama S, Masuda E, Miyabayashi H, Kimura T, Nishizawa Y, Takahashi M, Suzuki H. Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan. J Clin Gastroenterol. 2015;49:468-471. [PMID: 24921211 DOI: 10.1097/mcg.0000000000000165] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
41 Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Masaoka T, Kanai T. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation. Helicobacter. 2016;21:286-294. [PMID: 26612407 DOI: 10.1111/hel.12286] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
42 O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2011. Helicobacter. 2011;16 Suppl 1:53-58. [PMID: 21896086 DOI: 10.1111/j.1523-5378.2011.00881.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
43 Kim SE, Park MI, Park SJ, Moon W, Choi YJ, Cheon JH, Kwon HJ, Ku KH, Yoo CH, Kim JH. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30:801-807. [PMID: 26552455 DOI: 10.3904/kjim.2015.30.6.801] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
44 Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol. 2013;69:1709-1715. [PMID: 23695545 DOI: 10.1007/s00228] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 El Shahawy MS, Shady ZM, Gaafar A. Influence of adding vitamin D3 to standard clarithromycin-based triple therapy on the eradication rates of Helicobacter pylori infection. Arab J Gastroenterol 2021;22:209-14. [PMID: 34521593 DOI: 10.1016/j.ajg.2021.08.002] [Reference Citation Analysis]
46 Jin BH, Yoo BW, Park J, Kim JH, Lee JY, Shin JS, Park MS. Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study. Eur J Clin Pharmacol 2018;74:1149-57. [PMID: 29846770 DOI: 10.1007/s00228-018-2489-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol 2015;21:10644-53. [PMID: 26457024 DOI: 10.3748/wjg.v21.i37.10644] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
48 Hojo M, Asaoka D, Takeda T, Shimada Y, Matsumoto K, Matsumoto K, Yatagai N, Akazawa Y, Ueda K, Ueyama H, Nagahara A. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection. Therap Adv Gastroenterol 2020;13:1756284820966247. [PMID: 33240391 DOI: 10.1177/1756284820966247] [Reference Citation Analysis]
49 dos Santos AA, Carvalho AA. Pharmacological therapy used in the elimination of Helicobacter pylori infection: A review. World J Gastroenterol 2015; 21(1): 139-154 [PMID: 25574087 DOI: 10.3748/wjg.v21.i1.139] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
50 Ozeki K, Asano M, Furuta T, Ojima T. Relationship between primary eradication of Helicobacter pylori and drinking habits in women: collaborative research between a pharmacy and a clinic. Epidemiol Infect 2019;147:e292. [PMID: 31637982 DOI: 10.1017/S0950268819001730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Sahara S, Sugimoto M, Ichikawa H, Kagami T, Sakao Y, Ohashi N, Horio Y, Sugimoto K, Kato A, Furuta T. Efficacy of reduced dosage of amoxicillin in an eradication therapy for Helicobacter pylori infection in patients on hemodialysis: a randomized controlled trial. Digestion. 2018;97:163-169. [PMID: 29310119 DOI: 10.1159/000484981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Shah S, Hubscher E, Pelletier C, Jacob R, Vinals L, Yadlapati R. Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure. Expert Rev Gastroenterol Hepatol 2022;16:341-57. [PMID: 35315732 DOI: 10.1080/17474124.2022.2056015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Nishizawa T, Suzuki H, Fujimoto A, Kinoshita H, Yoshida S, Isomura Y, Toyoshima A, Kanai T, Yahagi N, Toyoshima O. Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. J Clin Biochem Nutr. 2017;60:208-210. [PMID: 28584402 DOI: 10.3164/jcbn.16-86] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
54 Huang X, Sun X, Yu X, Qian H. Efficacy and safety of Sijunzi Decoction for peptic ulcers: A systematic review and meta-analysis. Journal of Traditional Chinese Medical Sciences 2018;5:237-54. [DOI: 10.1016/j.jtcms.2018.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E, Wu O. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterol. 2016;16:80. [PMID: 27460211 DOI: 10.1186/s12876-016-0491-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
56 Mori H, Suzuki H, Matsuzaki J, Masaoka T, Kanai T. Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients. United European Gastroenterol J 2017;5:796-804. [PMID: 29026593 DOI: 10.1177/2050640616688995] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
57 Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012;2012:168361. [PMID: 22792095 DOI: 10.1155/2012/168361] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
58 Buzás GM. [Helicobacter pylori -- 2010]. Orv Hetil 2010;151:2003-10. [PMID: 21106480 DOI: 10.1556/OH.2010.28982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
59 Senatore FJ, Wilmot J, Birk JW. Helicobacter pylori treatment: Still a work in progress. Postgrad Med. 2016;128:152-157. [PMID: 26490697 DOI: 10.1080/00325481.2016.1103194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
60 Baba S, Oishi Y, Watanabe Y, Oikawa R, Morita R, Yoshida Y, Hiraishi T, Maehata T, Nagase Y, Fukuda Y. Gastric wash-based molecular testing for antibiotic resistance in Helicobacter pylori. Digestion. 2011;84:299-305. [PMID: 22057261 DOI: 10.1159/000332570] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
61 Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19:1637-1650. [PMID: 26245678 DOI: 10.1517/14728222.2015.1073261] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
62 Moss DM, Curley P, Kinvig H, Hoskins C, Owen A. The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. Expert Rev Gastroenterol Hepatol 2018;12:223-36. [PMID: 29088978 DOI: 10.1080/17474124.2018.1399794] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]